Throughout 2018, Lupus News Today brought you coverage of important discoveries, potential disease markers, treatment developments, and clinical trials related to lupus. As we look forward to reporting more news to patients, family members, and caregivers in 2019, here are the Top 10 most-read articles of 2018. No. 10 —…
European systemic lupus erythematosus (SLE) patients who produce autoantibodies against double-stranded DNA — a well-known biomarker of the disease — seem to benefit from the addition of Lupuzor (rigerimod) to their standard of care, new Phase 3 data suggest. In fact, more patients receiving the investigational add-on therapy experienced…
Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, failing the primary goal of a Phase 3 clinical trial, according to top-line results. Although not statistically significant, the investigational treatment did, however, show…
Top-line results of ImmuPharma’s Phase 3 clinical trial testing Lupuzor (rigerimod) as a systemic lupus erythematosus (SLE) treatment are expected by mid-April, according to the company. ImmuPharma also announced that database lock of the trial is expected by April 6. This milestone prevents unauthorized or unintended alterations to…
ImmuPharma has completed a pivotal Phase 3 clinical trial testing Lupuzor (rigerimod) as a lupus treatment and announced an extension study. Findings dealing with the therapy’s effectiveness are expected to be released by the end of April 2018. Lupuzor displayed a robust safety profile after being administered for a year, researchers…
New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed…
In a recent update on its pivotal Phase 3 clinical trial evaluating Lupuzor (rigerimod) as a potential treatment for lupus, ImmuPharma announced that it was complying with a request to open a trial site in Mauritius so that patients there could participate in the study. According to the company, the leading…
ImmuPharma, a specialized drug discovery and development pharmaceutical company, announced its Phase 3 clinical trial of Lupuzor (rigerimod), the company’s lead potential breakthrough lupus treatment candidate, has made progress and has begun dosing its first European patients. In its update, ImmunoPharma said the Lupuzor Phase 3 study will enroll…
ImmuPharma PLC and Simbec-Orion Group Limited recently announced a collaboration agreement for the execution of a Pivotal Phase III clinical study of ImmuPharma’s Lupuzor™, the company’s lead compound to treat Systemic Lupus Erythematosus, a chronic and life-threatening autoimmune disease. Lupuzor was granted Fast Track status by the Food and Drugs Administration (FDA); it…